DaVita Inc. provides kidney dialysis services, with a market cap of $8.7 billion. Stock has underperformed with a 17.7% decline in the past year. Q3 results show revenue at $3.4 billion, up 4.8% YoY, but adjusted EPS declined 14.9%. Analysts expect EPS to grow 8.7% to $10.52 for the year.

Despite efforts to manage costs and innovate, DaVita’s results suffered from lower treatment volumes, flu, Hurricane Helene, and a cyber incident. Shares closed down over 2% post Q3 results. Analyst consensus on DVA stock is “Hold,” with one “Strong Buy,” six “Holds,” one “Moderate Sell,” and one “Strong Sell.” Truist Financial Corporation analyst maintains a “Hold” rating with a price target of $140.

Read more at Yahoo Finance: DaVita Stock: Analyst Estimates & Ratings